Silverberg Donald S, Schwartz Doron
Department of Nephrology, Tel Aviv Medical Center, Weizman 6, Tel Aviv, Israel,
Curr Treat Options Cardiovasc Med. 2012 Aug;14(4):328-41. doi: 10.1007/s11936-012-0188-3.
The high prevalence of iron deficiency in heart failure (HF), its easy detection, and its rapid treatment effects with intravenous compounds including, among other things, improved New York Heart Association class, quality of life, and exercise capacity, may offer a major new addition to the treatment of HF. Although more research is required in HF, iron deficiency has been recognized as a disease for over a century and there is no question that its correction is desirable for improving the health and the quality of life of the iron-deficient patient. Iron deficiency with or without an associated anemia should be routinely searched for and treated in HF patients. Controlled studies of omega-3 fish oils suggest that they are cardioprotective in HF. They also may have additional value as safe and highly effective analgesics and anti-inflammatory agents in HF patients who often cannot take traditional nonsteroidal agents. The American Heart Association has recently recommended use of fish and/or fish supplements for all patients with cardiovascular disease. However, practical questions remain. For example, it is not clear what the optimal ratio of the two major components of fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), should be in supplements. The role of other vitamins, such as vitamin D, in HF remains unclear.
心力衰竭(HF)中铁缺乏症的高患病率、易于检测以及静脉注射化合物的快速治疗效果,包括改善纽约心脏协会分级、生活质量和运动能力等,可能为HF的治疗带来一项重大新进展。尽管在HF方面还需要更多研究,但铁缺乏症已被确认为一种疾病超过一个世纪,毫无疑问,纠正铁缺乏症对于改善缺铁患者的健康和生活质量是可取的。HF患者应常规检查并治疗有无相关贫血的铁缺乏症。对ω-3鱼油的对照研究表明,它们对HF具有心脏保护作用。它们在经常不能服用传统非甾体类药物的HF患者中,作为安全且高效的镇痛药和抗炎药可能还具有额外价值。美国心脏协会最近建议所有心血管疾病患者使用鱼类和/或鱼类补充剂。然而,实际问题仍然存在。例如,尚不清楚鱼油的两种主要成分二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)在补充剂中的最佳比例应该是多少。其他维生素,如维生素D,在HF中的作用仍不清楚。